Supplementary Figures and Legends from Characterization of &lt;i&gt;In Vivo&lt;/i&gt; Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance